Yh1 personal page - To The Moon

Yh1

Yh1

No personal profile

29Follow

2Followers

0Topic

0Badge

2021-07-23

Waiting foe growth stocks to go up.

Sorry, the original content has been removed

2021-08-23

So share price is going up

Sorry, the original content has been removed

2021-04-22

Is top glove going up?

Sorry, the original content has been removed

2021-09-03

Wow. I miss the boat again

Sorry, the original content has been removed

2021-06-30

Interesting

Sorry, the original content has been removed

2021-04-23

Hopefully we have a pm soon.

Sorry, the original content has been removed

2021-04-13

Is it good to invest

Sorry, the original content has been removed

2021-07-06

Hopping all go to the moon

Advaxis Jumps on Deal to Be Bought by Biosight

2021-04-13

Hopefully bank got higher

Sorry, the original content has been removed

2021-04-01

$Tesla Motors(TSLA)$Will telsa hit 700 today?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3558523389451047","uuid":"3558523389451047","gmtCreate":1595431279328,"gmtModify":1613569241844,"name":"Yh1","pinyin":"yh1","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":29,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.01.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.88%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":204461710520560,"gmtCreate":1690950643394,"gmtModify":1690950645796,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/P34.SI\">$DELFI LIMITED(P34.SI)$&nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/P34.SI\">$DELFI LIMITED(P34.SI)$&nbsp;</a>","text":"$DELFI LIMITED(P34.SI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/204461710520560","isVote":1,"tweetType":1,"viewCount":1949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889399728,"gmtCreate":1631108395764,"gmtModify":1676530469684,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Whalen is nano going up","listText":"Whalen is nano going up","text":"Whalen is nano going up","images":[{"img":"https://static.tigerbbs.com/13a8f68d2d2b577e725b154bf3ed339e","width":"750","height":"2326"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889399728","isVote":1,"tweetType":1,"viewCount":2137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815224635,"gmtCreate":1630682163527,"gmtModify":1676530376287,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Wow. I miss the boat again","listText":"Wow. I miss the boat again","text":"Wow. I miss the boat again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/815224635","repostId":"1105876391","repostType":4,"isVote":1,"tweetType":1,"viewCount":2737,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815225535,"gmtCreate":1630682120127,"gmtModify":1676530376271,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Cloudfare go go go","listText":"Cloudfare go go go","text":"Cloudfare go go go","images":[{"img":"https://static.tigerbbs.com/b8460287be535a4eefb1eaf8b9b8deb9","width":"750","height":"2380"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815225535","isVote":1,"tweetType":1,"viewCount":2412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815225120,"gmtCreate":1630682074660,"gmtModify":1676530376207,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NET\">$Cloudflare, Inc.(NET)$</a>Let’s go","listText":"<a href=\"https://laohu8.com/S/NET\">$Cloudflare, Inc.(NET)$</a>Let’s go","text":"$Cloudflare, Inc.(NET)$Let’s go","images":[{"img":"https://static.tigerbbs.com/296237cbee25f8280a3698b253e013f9","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815225120","isVote":1,"tweetType":1,"viewCount":2237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815222151,"gmtCreate":1630682018273,"gmtModify":1676530376184,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Please hit 800","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Please hit 800","text":"$Tesla Motors(TSLA)$Please hit 800","images":[{"img":"https://static.tigerbbs.com/d072a346ed5b0178d15b682d44f0f0c5","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815222151","isVote":1,"tweetType":1,"viewCount":1872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815222940,"gmtCreate":1630681997580,"gmtModify":1676530376184,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Please hit 800 please","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Please hit 800 please","text":"$Tesla Motors(TSLA)$Please hit 800 please","images":[{"img":"https://static.tigerbbs.com/d1e6bf431f084d64764686acaa4ac65b","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815222940","isVote":1,"tweetType":1,"viewCount":2399,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":835537670,"gmtCreate":1629726539390,"gmtModify":1676530112878,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"So share price is going up","listText":"So share price is going up","text":"So share price is going up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835537670","repostId":"1189910879","repostType":4,"isVote":1,"tweetType":1,"viewCount":2326,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175455448,"gmtCreate":1627047698784,"gmtModify":1703483236263,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Waiting foe growth stocks to go up.","listText":"Waiting foe growth stocks to go up.","text":"Waiting foe growth stocks to go up.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/175455448","repostId":"1164478982","repostType":4,"isVote":1,"tweetType":1,"viewCount":2978,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176175478,"gmtCreate":1626874730994,"gmtModify":1703479693911,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176175478","repostId":"2153610463","repostType":4,"isVote":1,"tweetType":1,"viewCount":1847,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171872428,"gmtCreate":1626739855664,"gmtModify":1703764127582,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Let try to buy some good stocks.&nbsp;","listText":"Let try to buy some good stocks.&nbsp;","text":"Let try to buy some good stocks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/171872428","repostId":"2152483637","repostType":4,"isVote":1,"tweetType":1,"viewCount":1139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171876027,"gmtCreate":1626739806969,"gmtModify":1703764124817,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Is lemonade really a good stock?","listText":"Is lemonade really a good stock?","text":"Is lemonade really a good stock?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171876027","repostId":"2152658489","repostType":4,"isVote":1,"tweetType":1,"viewCount":967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141843140,"gmtCreate":1625850319980,"gmtModify":1703749926061,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"AMC to the moon&nbsp;","listText":"AMC to the moon&nbsp;","text":"AMC to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141843140","repostId":"1173374462","repostType":4,"repost":{"id":"1173374462","kind":"news","pubTimestamp":1625840008,"share":"https://ttm.financial/m/news/1173374462?lang=en_US&edition=fundamental","pubTime":"2021-07-09 22:13","market":"us","language":"en","title":"Meme Stocks Like GameStop and AMC Reflect Market Reality","url":"https://stock-news.laohu8.com/highlight/detail?id=1173374462","media":"Thestreet","summary":"Gamestop (GME) made some investors rich… and then it broke many more. Investing in AMC Entertainment","content":"<p>Gamestop&nbsp;(<b>GME</b>)&nbsp;made some investors rich… and then it broke many more. Investing in AMC Entertainment&nbsp;(<b>AMC</b>)&nbsp;did the exact same thing. These two stocks represent, if not failing businesses, at least ailing ones; companies that struggled to keep up with the new economy even before the pandemic shut down large swaths of it. Yet over the past few months they have posted some of the most volatile gains and losses on the market.</p>\n<p>How?</p>\n<p>It’s down to what Real Money's Timothy Collins calls the market of “meme stock hyperbole.” But, he writes, is it really all that different from how trading has always worked?</p>\n<p>Have you ever really thought about the phrases 'to the moon' or 'conviction buy,' and how they mess with out perception of fair value?</p>\n<p>\"Initially, I rolled my eyes at the continued use of the phrase 'To The Moon,'\" Collins says. \"It's not like 'Strong Buy with a price target of $65', for instance. 'To the moon' is completely arbitrary and open to interpretation, but then again so are most things about valuation, when you think about it,\" Collins wrote.</p>\n<p>\"For instance, when an analyst pounds the table on a stock, how is that different from 'to the moon?' Or when someone says, 'all in.' Are they really all in? Did they cash in all their assets, pool the liquidity, and buy every share they possibly could? Probably not. Actually, I'd say definitely not 99.9999% of the time. Of course, there's always that one person,\" Collins said.</p>\n<p>\"But the point isWall Street has been arbitraryfor years. We can't even have a standard rating system. Is it 'Neutral' or 'Hold?' And really, do I want to hold something that is only in the middle of your range? No.\"</p>\n<p>Collins writes, \"The system should be 'buy' or 'sell.' That's it. Black or white. Own or don't own.\"</p>\n<p>Assets like GameStop and even cryptocurrency seem to be selling on nothing more than pure emotion. Investors are taking these products for a joy ride, and that tends to send prices flying up and down the ladder.</p>\n<p>That’s confusing, to be sure. Just, before you go throwing your hands in the air, it’s important to remember that the stock market has always been at least a little bit arbitrary.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme Stocks Like GameStop and AMC Reflect Market Reality</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme Stocks Like GameStop and AMC Reflect Market Reality\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/meme-stocks-like-gamestop-amc-reflect-market-reality><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gamestop (GME) made some investors rich… and then it broke many more. Investing in AMC Entertainment (AMC) did the exact same thing. These two stocks represent, if not failing businesses, at least ...</p>\n\n<a href=\"https://www.thestreet.com/investing/meme-stocks-like-gamestop-amc-reflect-market-reality\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","GME":"游戏驿站"},"source_url":"https://www.thestreet.com/investing/meme-stocks-like-gamestop-amc-reflect-market-reality","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173374462","content_text":"Gamestop (GME) made some investors rich… and then it broke many more. Investing in AMC Entertainment (AMC) did the exact same thing. These two stocks represent, if not failing businesses, at least ailing ones; companies that struggled to keep up with the new economy even before the pandemic shut down large swaths of it. Yet over the past few months they have posted some of the most volatile gains and losses on the market.\nHow?\nIt’s down to what Real Money's Timothy Collins calls the market of “meme stock hyperbole.” But, he writes, is it really all that different from how trading has always worked?\nHave you ever really thought about the phrases 'to the moon' or 'conviction buy,' and how they mess with out perception of fair value?\n\"Initially, I rolled my eyes at the continued use of the phrase 'To The Moon,'\" Collins says. \"It's not like 'Strong Buy with a price target of $65', for instance. 'To the moon' is completely arbitrary and open to interpretation, but then again so are most things about valuation, when you think about it,\" Collins wrote.\n\"For instance, when an analyst pounds the table on a stock, how is that different from 'to the moon?' Or when someone says, 'all in.' Are they really all in? Did they cash in all their assets, pool the liquidity, and buy every share they possibly could? Probably not. Actually, I'd say definitely not 99.9999% of the time. Of course, there's always that one person,\" Collins said.\n\"But the point isWall Street has been arbitraryfor years. We can't even have a standard rating system. Is it 'Neutral' or 'Hold?' And really, do I want to hold something that is only in the middle of your range? No.\"\nCollins writes, \"The system should be 'buy' or 'sell.' That's it. Black or white. Own or don't own.\"\nAssets like GameStop and even cryptocurrency seem to be selling on nothing more than pure emotion. Investors are taking these products for a joy ride, and that tends to send prices flying up and down the ladder.\nThat’s confusing, to be sure. Just, before you go throwing your hands in the air, it’s important to remember that the stock market has always been at least a little bit arbitrary.","news_type":1,"symbols_score_info":{"GME":0.9,"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":1021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141843914,"gmtCreate":1625850284538,"gmtModify":1703749925240,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Lousy stock, it just keep dropping. When are you going to go up","listText":"Lousy stock, it just keep dropping. When are you going to go up","text":"Lousy stock, it just keep dropping. When are you going to go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141843914","repostId":"1158342403","repostType":4,"repost":{"id":"1158342403","kind":"news","pubTimestamp":1625840608,"share":"https://ttm.financial/m/news/1158342403?lang=en_US&edition=fundamental","pubTime":"2021-07-09 22:23","market":"us","language":"en","title":"Tesla Shares Form Death Cross, Portending Further Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=1158342403","media":"Bloomberg","summary":"(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders ","content":"<p><img src=\"https://static.tigerbbs.com/bb51ddaee6b764108c6a043b0481069f\" tg-width=\"704\" tg-height=\"396\" referrerpolicy=\"no-referrer\">(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders as it often precedes further losses for the stock.</p>\n<p>The short-term average price for the stock fell below the long-term average, forming a so-called death cross. Shares of the electric vehicle maker have been on a rough ride already this year, falling 8%, even as the broader market rose nearly 16%.</p>\n<p>The decline reflects growing investor concern about competition from traditional carmakers that are pushing aggressively into the EV race, as well as the company’s future growth trajectory in China, which is among the world’s biggest markets for automobiles. On Thursday, Tesla unveiled a significantly cheaper version of its Model Y car in the country, even as its China deliveries dropped last month.</p>\n<p>The last time Tesla shares formed this trading pattern was in February 2019, and it preceded a more than 40% decline in the share price within 65 days, to $35.79 from $63.98.</p>\n<p>Tesla shares dropped as much as 1.2% on Friday in New York. Shares of smaller EV startups also languished, with Workhorse Group Inc. and XPeng Inc. among the biggest decliners in the group.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Shares Form Death Cross, Portending Further Declines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Shares Form Death Cross, Portending Further Declines\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tesla-shares-form-death-cross-140046201.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders as it often precedes further losses for the stock.\nThe short-term average price for the stock fell ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tesla-shares-form-death-cross-140046201.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/tesla-shares-form-death-cross-140046201.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158342403","content_text":"(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders as it often precedes further losses for the stock.\nThe short-term average price for the stock fell below the long-term average, forming a so-called death cross. Shares of the electric vehicle maker have been on a rough ride already this year, falling 8%, even as the broader market rose nearly 16%.\nThe decline reflects growing investor concern about competition from traditional carmakers that are pushing aggressively into the EV race, as well as the company’s future growth trajectory in China, which is among the world’s biggest markets for automobiles. On Thursday, Tesla unveiled a significantly cheaper version of its Model Y car in the country, even as its China deliveries dropped last month.\nThe last time Tesla shares formed this trading pattern was in February 2019, and it preceded a more than 40% decline in the share price within 65 days, to $35.79 from $63.98.\nTesla shares dropped as much as 1.2% on Friday in New York. Shares of smaller EV startups also languished, with Workhorse Group Inc. and XPeng Inc. among the biggest decliners in the group.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":709,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157660550,"gmtCreate":1625580558370,"gmtModify":1703744294705,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Hopping all go to the moon","listText":"Hopping all go to the moon","text":"Hopping all go to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157660550","repostId":"1118465420","repostType":4,"repost":{"id":"1118465420","kind":"news","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=en_US&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1,"symbols_score_info":{"ADXS":0.9}},"isVote":1,"tweetType":1,"viewCount":739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153186048,"gmtCreate":1625013621284,"gmtModify":1703850040995,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153186048","repostId":"2147898672","repostType":4,"isVote":1,"tweetType":1,"viewCount":795,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105854636,"gmtCreate":1620292065625,"gmtModify":1704341435727,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LKCO\">$Luokung Technology Corp(LKCO)$</a>Hopefully the stock will move to Ath now","listText":"<a href=\"https://laohu8.com/S/LKCO\">$Luokung Technology Corp(LKCO)$</a>Hopefully the stock will move to Ath now","text":"$Luokung Technology Corp(LKCO)$Hopefully the stock will move to Ath now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105854636","isVote":1,"tweetType":1,"viewCount":1042,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108452817,"gmtCreate":1620050758939,"gmtModify":1704337917607,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Let’s go higher","listText":"Let’s go higher","text":"Let’s go higher","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108452817","repostId":"1165463758","repostType":4,"isVote":1,"tweetType":1,"viewCount":837,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108456791,"gmtCreate":1620050741613,"gmtModify":1704337918094,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Way to go","listText":"Way to go","text":"Way to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108456791","repostId":"1125593862","repostType":4,"repost":{"id":"1125593862","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620050268,"share":"https://ttm.financial/m/news/1125593862?lang=en_US&edition=fundamental","pubTime":"2021-05-03 21:57","market":"us","language":"en","title":"U.S. stock benchmarks open higher to start May trade. Dow rose 1% for now","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593862","media":"Tiger Newspress","summary":"(May 3) U.S. stock benchmarks open higher to start May trade. Dow rose 1% for now.","content":"<p>(May&nbsp;3)&nbsp;U.S. stock benchmarks open higher to start May trade. Dow rose 1% for now.</p><p><img src=\"https://static.tigerbbs.com/b00fdc29ae0463ac42f782eb04e4ab06\" tg-width=\"911\" tg-height=\"479\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock benchmarks open higher to start May trade. Dow rose 1% for now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock benchmarks open higher to start May trade. Dow rose 1% for now\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-03 21:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(May&nbsp;3)&nbsp;U.S. stock benchmarks open higher to start May trade. Dow rose 1% for now.</p><p><img src=\"https://static.tigerbbs.com/b00fdc29ae0463ac42f782eb04e4ab06\" tg-width=\"911\" tg-height=\"479\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125593862","content_text":"(May 3) U.S. stock benchmarks open higher to start May trade. Dow rose 1% for now.","news_type":1,"symbols_score_info":{".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":898,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103571741,"gmtCreate":1619796641183,"gmtModify":1704272563996,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Test","listText":"Test","text":"Test","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/103571741","repostId":"1165708828","repostType":4,"repost":{"id":"1165708828","kind":"news","pubTimestamp":1619792862,"share":"https://ttm.financial/m/news/1165708828?lang=en_US&edition=fundamental","pubTime":"2021-04-30 22:27","market":"us","language":"en","title":"3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1165708828","media":"Motley Fool","summary":"For more than a year, patient investors have been handsomely rewarded. All three of the market's maj","content":"<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.</p>\n<p>Yet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in the<b>S&amp;P 500</b>,<b>Dow Jones Industrial Average</b>, and<b>Nasdaq Composite</b>, this represents a huge underperformance.</p>\n<p>But according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.</p>\n<p>Sarepta Therapeutics: Implied upside of 91%</p>\n<p>Many of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developer<b>Sarepta Therapeutics</b>(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.</p>\n<p>Sarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.</p>\n<p>However, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.&nbsp; In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.</p>\n<p>The Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.</p>\n<p>Intercept Pharmaceuticals: Implied upside of 97%</p>\n<p>If you wanteven more upside potential, Wall Street would steer you toward small-cap<b>Intercept Pharmaceuticals</b>(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.</p>\n<p>Similar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.</p>\n<p>Intercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.</p>\n<p>On the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.</p>\n<p>If OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.</p>\n<p>It's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.</p>\n<p>Inovio Pharmaceuticals: Implied upside of 104%</p>\n<p>Yet another biotech stock withbig-time upside potential, according to Wall Street, is<b>Inovio Pharmaceuticals</b>(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.</p>\n<p>For much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.</p>\n<p>Unfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.</p>\n<p>There are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players like<b>Johnson &amp; Johnson</b>&nbsp;can produce up to 3 billion doses for the global market this year. As a reminder, J&amp;J's vaccine is a single-dose treatment.</p>\n<p>The other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.</p>\n<p>With a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165708828","content_text":"For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.\nYet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in theS&P 500,Dow Jones Industrial Average, andNasdaq Composite, this represents a huge underperformance.\nBut according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.\nSarepta Therapeutics: Implied upside of 91%\nMany of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developerSarepta Therapeutics(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.\nSarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.\nHowever, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.  In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.\nThe Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.\nIntercept Pharmaceuticals: Implied upside of 97%\nIf you wanteven more upside potential, Wall Street would steer you toward small-capIntercept Pharmaceuticals(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.\nSimilar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.\nIntercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.\nOn the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.\nIf OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.\nIt's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.\nInovio Pharmaceuticals: Implied upside of 104%\nYet another biotech stock withbig-time upside potential, according to Wall Street, isInovio Pharmaceuticals(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.\nFor much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.\nUnfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.\nThere are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players likeJohnson & Johnson can produce up to 3 billion doses for the global market this year. As a reminder, J&J's vaccine is a single-dose treatment.\nThe other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.\nWith a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":175455448,"gmtCreate":1627047698784,"gmtModify":1703483236263,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Waiting foe growth stocks to go up.","listText":"Waiting foe growth stocks to go up.","text":"Waiting foe growth stocks to go up.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/175455448","repostId":"1164478982","repostType":4,"isVote":1,"tweetType":1,"viewCount":2978,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835537670,"gmtCreate":1629726539390,"gmtModify":1676530112878,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"So share price is going up","listText":"So share price is going up","text":"So share price is going up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835537670","repostId":"1189910879","repostType":4,"isVote":1,"tweetType":1,"viewCount":2326,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376889405,"gmtCreate":1619102435207,"gmtModify":1704719724140,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Is top glove going up?","listText":"Is top glove going up?","text":"Is top glove going up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/376889405","repostId":"1150823744","repostType":4,"isVote":1,"tweetType":1,"viewCount":962,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815224635,"gmtCreate":1630682163527,"gmtModify":1676530376287,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Wow. I miss the boat again","listText":"Wow. I miss the boat again","text":"Wow. I miss the boat again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/815224635","repostId":"1105876391","repostType":4,"isVote":1,"tweetType":1,"viewCount":2737,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153186048,"gmtCreate":1625013621284,"gmtModify":1703850040995,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153186048","repostId":"2147898672","repostType":4,"isVote":1,"tweetType":1,"viewCount":795,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":372978633,"gmtCreate":1619172864122,"gmtModify":1704720758726,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Hopefully we have a pm soon.","listText":"Hopefully we have a pm soon.","text":"Hopefully we have a pm soon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/372978633","repostId":"1143062408","repostType":4,"isVote":1,"tweetType":1,"viewCount":608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":345489933,"gmtCreate":1618329589822,"gmtModify":1704709323687,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Is it good to invest","listText":"Is it good to invest","text":"Is it good to invest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/345489933","repostId":"1194635432","repostType":4,"isVote":1,"tweetType":1,"viewCount":578,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157660550,"gmtCreate":1625580558370,"gmtModify":1703744294705,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Hopping all go to the moon","listText":"Hopping all go to the moon","text":"Hopping all go to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157660550","repostId":"1118465420","repostType":4,"repost":{"id":"1118465420","kind":"news","pubTimestamp":1625580135,"share":"https://ttm.financial/m/news/1118465420?lang=en_US&edition=fundamental","pubTime":"2021-07-06 22:02","market":"us","language":"en","title":"Advaxis Jumps on Deal to Be Bought by Biosight","url":"https://stock-news.laohu8.com/highlight/detail?id=1118465420","media":"Thestreet","summary":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Bi","content":"<p>Advaxis&nbsp;(<b>ADXS</b>)&nbsp;shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.</p>\n<p>At closing, Biosight holders will own 75%&nbsp;of the company and&nbsp;Advaxis holders will own 25%.</p>\n<p>Advaxis,&nbsp;Princeton, N.J.,&nbsp;recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.</p>\n<p>The combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.</p>\n<p>“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.</p>\n<p>The new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.</p>\n<p>In other healthcare news, Iterum Therapeutics&nbsp;(<b>ITRM</b>) -Get Report&nbsp;said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections&nbsp;were found.</p>\n<p>The Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.</p>\n<p>Also last week,Anavex Life Sciences&nbsp;(<b>AVXL</b>) -Get Report&nbsp;reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.</p>\n<p>JonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Advaxis Jumps on Deal to Be Bought by Biosight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdvaxis Jumps on Deal to Be Bought by Biosight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/advaxis-to-be-bought-by-biosight-of-israel-for-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118465420","content_text":"Advaxis (ADXS) shares were higher Monday after the company agreed to be purchased by peer biotech Biosight of Lod, Israel, for stock.\nAt closing, Biosight holders will own 75% of the company and Advaxis holders will own 25%.\nAdvaxis, Princeton, N.J., recently traded at 70 cents a share, up 48%. It had gained 5% in the six months through Friday.\nThe combined company will be named Biosight Therapeutics and trade on Nasdaq with the ticker symbol BSTX.\n“The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine,” the companies said. That drug treats acute myeloid leukemia.\nThe new company is expected to have some $50 million cash, cash equivalents and marketable securities. The deal is expected to close in the second half, subject to conditions including regulatory clearances and votes of holders of both companies.\nIn other healthcare news, Iterum Therapeutics (ITRM) -Get Report said Friday that it received a letterfrom the FDA saying that deficiencies in its treatment for urinary-tract infections were found.\nThe Food and Drug Administration letter stated that as “part of their ongoing review of the company’s new drug application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post-marketing requirements/commitments at this time,” Iterum said.\nAlso last week,Anavex Life Sciences (AVXL) -Get Report reported progress in a Phase 2 trial of a Parkinson’s drug, Anavex2-73.\nJonesTrading analyst Soumit Roy raised his price target on the New York company to $50 from $35, affirming a buy rating.","news_type":1,"symbols_score_info":{"ADXS":0.9}},"isVote":1,"tweetType":1,"viewCount":739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":345665743,"gmtCreate":1618310456282,"gmtModify":1704708932356,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"Hopefully bank got higher","listText":"Hopefully bank got higher","text":"Hopefully bank got higher","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/345665743","repostId":"1102483578","repostType":4,"isVote":1,"tweetType":1,"viewCount":399,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":357257563,"gmtCreate":1617281382852,"gmtModify":1704698227433,"author":{"id":"3558523389451047","authorId":"3558523389451047","name":"Yh1","avatar":"https://static.tigerbbs.com/2c577f92c97c37d7b33594dcf2b56891","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3558523389451047","idStr":"3558523389451047"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Will telsa hit 700 today?","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Will telsa hit 700 today?","text":"$Tesla Motors(TSLA)$Will telsa hit 700 today?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/357257563","isVote":1,"tweetType":1,"viewCount":1238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}